Henry Schein, Inc. (NASDAQ:HSIC) Receives $76.69 Average Target Price from Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $76.4167.

Several brokerages recently weighed in on HSIC. JPMorgan Chase & Co. boosted their price target on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Barrington Research set a $79.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Morgan Stanley increased their price target on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a report on Wednesday, November 5th. Finally, Mizuho set a $81.00 price target on Henry Schein and gave the stock a “neutral” rating in a research report on Tuesday.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently modified their holdings of HSIC. AQR Capital Management LLC boosted its stake in Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after buying an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Henry Schein in the 1st quarter worth about $676,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Henry Schein by 5.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,277 shares of the company’s stock worth $4,202,000 after purchasing an additional 3,143 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Henry Schein by 165.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 45,066 shares of the company’s stock valued at $3,292,000 after purchasing an additional 28,089 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Down 1.6%

Shares of Henry Schein stock opened at $77.21 on Wednesday. The firm has a market cap of $9.09 billion, a price-to-earnings ratio of 24.43, a PEG ratio of 2.33 and a beta of 0.88. The business has a 50-day moving average price of $75.85 and a 200-day moving average price of $70.70. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The company had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Equities research analysts anticipate that Henry Schein will post 4.74 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.